| Literature DB >> 19406473 |
Elise Chapiro1, Nathalie Leporrier, Isabelle Radford-Weiss, Christian Bastard, Hossein Mossafa, Dominique Leroux, Isabelle Tigaud, Marc De Braekeleer, Christine Terré, Françoise Brizard, Evelyne Callet-Bauchu, Stéphanie Struski, Lauren Veronese, Sandra Fert-Ferrer, Sylvie Taviaux, Claude Lesty, Frédéric Davi, Hélène Merle-Béral, Olivier A Bernard, Laurent Sutton, Sophie D Raynaud, Florence Nguyen-Khac.
Abstract
Using array-based CGH, we identified 2p gain in 22/78 (28%) untreated Binet stages B/C CLL, which was the second most frequent copy number change after 13q deletion. It never occurred as a sole abnormality and was associated with other changes (6q deletion; 1p gain). The region of 2p gain frequently included two oncogenes, REL and MYCN. All patients with gain of REL were unmutated for IGHV (p=0.03). Gain of MYCN was associated with increased mRNA expression (p=0.005), suggesting a pathogenic role for MYCN. Gain of 2p appears to be a marker of progression and may contribute to the poor prognosis. 2009 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Year: 2009 PMID： 19406473 DOI： 10.1016/j.leukres.2009.03.042
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156